What's the Problem?

Diseases such as hemophilia, arthritis or cancer are well known. The key to their treatment lies in glycosylated proteins. However, the traditional method of using mammalian cells for production faces three main obstacles: low productivity, scalability challenges, and low glycosylation quality. Unfortunately, this compromises the efficacy and safety of treatments. Yeast offers a viable alternative for producing these proteins. However, their application in the pharmaceutical industry has been limited mainly due to the glycosylation they perform, which can compromise the effectiveness and safety of treatments. Previous attempts to improve glycosylation by humanizing yeasts have proven to be unstable, resulting in reduced production yields and the emergence of undesirable modifications. This is precisely where Dogma comes in to provide a solution.